In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi

International Journal of Antimicrobial Agents

Volumn 32, Issue 5, 2008, Pages 418-420

  Ruíz Cendoya, Mery ^a   Rodriguez, M Mar ^a   Mariné, Marçal ^a   Pastor, F Javier ^a   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

Author keywords

Aspergillus; Itraconazole; Micafungin; Synergy

Indexed keywords

ITRACONAZOLE; MICAFUNGIN;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; FONSECAEA; FUNGAL STRAIN; FUSARIUM OXYSPORUM; FUSARIUM SOLANI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PAECILOMYCES LILACINUS; PETRIELLIDIUM BOYDII; PRIORITY JOURNAL; SCEDOSPORIUM; SPOROTHRIX SCHENCKII;

ANTIFUNGAL AGENTS; DRUG SYNERGISM; ECHINOCANDINS; FUNGI; ITRACONAZOLE; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MYCOSES; QUALITY CONTROL;

EID: 53249154651     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.05.015     Document Type: Article

References (32)

1. Kauffman C.A. Fungal infections. Proc Am Thorac Soc 3 (2006) 35-40
2. Walsh T.J., Groll A., Hiemenz J., Fleming R., Roilides E., and Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 10 (2004) 48-66
3. Lemke A., Kiderlen A.F., and Kayser O. Amphotericin B. Appl Microbiol Biotechnol 68 (2005) 151-162
4. Azor M., Gene J., Cano J., and Guarro J. Universal in vitro antifungal resistance of genetic clades of the Fusarium solani species complex. Antimicrob Agents Chemother 51 (2007) 1500-1503
5. Gilgado F., Serena C., Cano J., Gene J., and Guarro J. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 50 (2006) 4211-4213
6. Marimón R., Serena C., Gené J., Cano J., and Guarro J. In vitro antifungal susceptibilities of 5 species of Sporothrix. Antimicrob Agents Chemother 52 (2008) 732-734
7. Clemons K.V., and Stevens D.A. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr Opin Infect Dis 19 (2006) 360-364
8. Kontoyiannis D.P., and Lewis R.E. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us so far. Drug Resist Updat 6 (2003) 257-269
9. Furugen M., Haranaga S., Touyama M., Shiroma R., Yara S., Shinzato T., et al. Two cases of pulmonary aspergillosis successfully treated with combined micafungin and itraconazole therapy. Kansenshogaku Zasshi 79 (2005) 951-956 [in Japanese]
10. Maruyama T., Takagi T., and Yuda H. Combination therapy of micafungin and itraconazole for a case of pulmonary aspergillosis. Nihon Kokyuki Gakkai Zasshi 43 (2005) 94-98 [in Japanese]
11. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. Document M38-A. Wayne, PA: NCCLS; 2002.
12. Eliopoulos G.M., and Moellering R.C. Antimicrobial combinations. In: Lorian V. (Ed). Antibiotics in laboratory medicine. 3rd ed. (1991), Williams & Wilkins Co., Baltimore, MD 432-492
13. Capilla J., Ortoneda M., Pastor F.J., and Guarro J. In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi. Antimicrob Agents Chemother 45 (2001) 2635-2637
14. Arikan S., Lozano-Chiu M., Paetznick V., and Rex J.H. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 46 (2002) 245-247
15. Pastor F.J., and Guarro J. In vitro activity of the echinocandins. How it can be evaluated?. Rev Iberoam Micol 22 (2005) 133-140 [in Spanish]
16. Mukherjee P.K., Sheehan D.J., Hitchcock C.A., and Ghannoum M.A. Combination treatment of invasive fungal infections. Clin Microbiol Rev 18 (2005) 163-164
17. Johnson M.D., MacDougall C., Ostrosky-Zeichner L., Perfect J.R., and Rex J.H. Combination antifungal therapy. Antimicrob Agents Chemother 48 (2004) 693-715
18. Cuenca-Estrella M., Gomez-Lopez A., Mellado E., Buitrago M.J., Monzon A., and Rodriguez-Tudela J.L. Head-to-head comparison of the activities of currently available antifungal agents against 3378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 50 (2006) 917-921
19. Philip A., Odabasi Z., Rodriguez J., Paetznick V.L., Chen E., Rex J.H., et al. In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. Antimicrob Agents Chemother 49 (2005) 3572-3574
20. Clemons K., and Stevens D.A. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol 44 (2006) 69-73
21. Jarvis B., Figgitt D.P., and Scott L.J. Micafungin Drugs 64 (2004) 969-982
22. Prentice A.G., and Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 56 (2005) 17-22
23. Pastor F.J., and Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect 12 (2006) 948-960
24. Nucci M., and Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 20 (2007) 695-704
25. Johnson E.M., Szekely A., and Warnock D.W. In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 42 (1998) 741-745
26. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12.052 fungal isolates: review of the literature. Rev Iberoam Micol 20 (2003) 121-136
27. Sabatelli F., Patel R., Mann P.A., Mendrick C.A., Norris C.C., Hare R., et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 50 (2006) 2009-2015
28. Ortoneda M., Capilla J., Pastor F.J., Pujol I., Serena C., and Guarro J. In vitro interactions of approved and novel drugs against Paecilomyces spp. Antimicrob Agents Chemother 48 (2004) 2727-2729
29. Cuenca-Estrella M., Alastruey-Izquierdo A., Alcazar-Fuoli L., Bernal-Martinez L., Gomez-Lopez A., Buitrago M.J., et al. In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans. Antimicrob Agents Chemother 52 (2008) 1136-1139
30. Queiroz-Telles F., Purim K.S., Fillus J.N., Bordignon G.F., Lameira R.P., Van Cutsem J., et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea pedrosoi. Int J Dermatol 31 (1992) 805-812
31. Sharkey-Mathis P.K., Kauffman C.A., Graybill J.R., Stevens D.A., Hostetler J.S., Cloud G., et al. Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med 95 (1993) 279-285
32. Guarro J., Kantarcioglu A.S., Horre R., Rodriguez-Tudela J.L., Cuenca Estrella M., Berenguer J., et al. Scedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunist. Med Mycol 44 (2006) 295-327